In this interview we speak to José Javier García from Pivotal about his company´s involvement in a large-scale clinical trial testing the safety and efficacy of hyperimmune convalescent plasma treatment in COVID-19 patients.
In this interview we speak to Jonathan Kurtis (Brown University, RI, USA) about the discovery of a parasite protein that provides new insights into how malaria regulates infection levels within its host, along with new possibilities for a broadly effective vaccine and a new class of antimalarial drugs.
Data from the Adaptive COVID-19 Treatment Trial (ACTT) has demonstrated that remdesivir treatment reduces recovery time in patients hospitalized with severe SARS-CoV-2 infections, requiring supplemental oxygen therapy. The results support remdesivir as the standard treatment for patients hospitalized with COVID-19.
A drug repurposing survey has identified 30 existing drugs, previously approved for treatment in other diseases, that could be successful in treating COVID-19.
The first clinical trial assessing two triple artemisinin-based combination therapies (TACTs) for treating malaria has suggested these are effective and present no safety concerns.
Long-term follow-up of the ‘London patient’, the second patient to ever achieve sustained HIV remission after ceasing antiretroviral treatment, has suggested that there is no active detectable HIV virus remaining.
Take a look a this overview of precision medicine; the concept, benefits, road blocks and what the future might hold.
Take a look behind the scenes of a recent Future Virology article, entitled ‘Update on HIV integrase inhibitors for the treatment of HIV’, as we ask the authors about these drugs for HIV treatment and the future of this field.
In this interview, we speak to Jenn Edwards from the Abigail Wexner Research Institute (OH, USA) about her research using the primary human epithelial cell models to examine Neisseria gonorrhoeae infections, the potential for vaccination against gonorrhea and a possible host-targeted therapy for this infection.
In this infographic we take a look at the long-acting formulations for HIV prevention and treatment currently in the clinical pipeline – from Phase I to approval.
